BioPorto Diagnostics is an in-vitro diagnostic company that provides biomarkers, research antibodies, and assays to scientists and clinicians. Its main product is a neutrophil gelatinase-associated lipocalin (NGAL) Test that aids in the rapid risk assessment of acute kidney injury (AKI) in critically ill patients by measuring the NGAL biomarker associated with renal tubular injury. The company also offers Rapid Assay Device (gRAD), a platform technology that is designed to facilitate the development of custom lateral flow assays. In addition, BioPorto Diagnostics offers specific antibodies suitable for research into clinical conditions such as AKI, obesity, diabetes, innate immunity, allergy, and infectious diseases.